Nexstim

Executive Summary

Nexstim is a Finnish medical technology company specializing in navigated Transcranial Magnetic Stimulation (nTMS) systems, which combine 3D imaging and E-field visualization for precise brain stimulation. Founded in 2000, the company targets challenging neurological and psychiatric disorders, offering both therapeutic and diagnostic applications. Its proprietary technology enables personalized, non-invasive treatment planning, positioning Nexstim as a potential leader in the emerging brain stimulation market. While still private, Nexstim has built a strong intellectual property portfolio and a pipeline aimed at expanding indications, including major depressive disorder and stroke rehabilitation. The company faces competition from established players like Magstim and NeuroStar but differentiates through its navigation and dose quantification features. Key risks include regulatory hurdles, commercialization challenges, and reliance on reimbursement. Despite these, Nexstim's innovative platform and growing clinical evidence support a moderate conviction in its long-term value creation potential.

Upcoming Catalysts (preview)

• Q4 2026FDA 510(k) clearance for Nexstim's nTMS system in major depressive disorder70% success
• Q3 2026Publication of pivotal trial results for stroke rehabilitation using nTMS80% success
• Q1 2027Strategic partnership with a major pharmaceutical or device company for distribution50% success